0001213900-13-007323.txt : 20131220 0001213900-13-007323.hdr.sgml : 20131220 20131219173811 ACCESSION NUMBER: 0001213900-13-007323 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20131219 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20131220 DATE AS OF CHANGE: 20131219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OxySure Systems Inc CENTRAL INDEX KEY: 0001413797 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 710960725 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54137 FILM NUMBER: 131289180 BUSINESS ADDRESS: STREET 1: 10880 JOHN W. ELLIOTT ROAD STREET 2: SUITE 600 CITY: Frisco STATE: TX ZIP: 75034 BUSINESS PHONE: (972) 294-6450 MAIL ADDRESS: STREET 1: 10880 JOHN W. ELLIOTT ROAD STREET 2: SUITE 600 CITY: Frisco STATE: TX ZIP: 75034 8-K 1 f8k080213_oxysure.htm CURRENT REPORT f8k080213_oxysure.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report December 19, 2013
 
OxySure Systems, Inc.
(Exact name of registrant as specified in its chapter)
 
Delaware
(State or other jurisdiction of incorporation)
000-54137
(Commission File Number)
71-0960725
(IRS Employer Identification No.)

10880 John W. Elliott Drive, Suite 600, Frisco, TX
(Address of principal executive offices)
75033
(Zip Code)

(972) 294-6450
(Registrant's telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Section 8 – Other Events

Item 8.01 Other Events.

On November 18, 2013, OxySure Systems, Inc. (“OxySure” or the “Company”) issued a press release announcing that the Company has entered into a distribution agreement with Pacific Medical Systems Ltd. A copy of the press release is furnished with this report as Exhibit 99.1.
 
Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01 Financial Statements and Exhibits
 
(d) Exhibit 99.1 Press Release dated December 18, 2013; furnished not filed.
 
 
2
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: December 19, 2013
   
 
OXYSURE SYSTEMS, INC.,
a Delaware corporation
 
   
/s/ Julian T. Ross
 
BY:  
Julian T. Ross
 
ITS: 
Chief Executive Officer, President,
Chief Financial Officer, and Secretary
 
 
3
 EX-99.1 2 f8k080213ex99i_oxysure.htm PRESS RELEASE f8k080213ex99i_oxysure.htm
Exhibit 99.1
 

OxySure Systems (OXYS) Expands to Hong Kong and Macau

FRISCO, Texas, December 18, 2013, 2013 (MarketWired) -- OxySure(R) Systems, Inc. (OXYS: OTCQB) ("OxySure," or the "Company"), a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology, today announced that Pacific Medical Systems, Ltd. has signed an agreement to be the Company’s exclusive distributor for OxySure’s products in Hong Kong and Macau.

“We are pleased to add Pacific Medical Systems to our growing list of global distribution partners,” stated Mr. Julian Ross, CEO of OxySure. “Pacific Medical Systems has been a trailblazer in the sale of AEDs in Hong Kong and we look forward to working with Jules Flach and his team to estabish a strong presence in Hong Kong and Macau for OxySure. What is unique about Hong Kong in particular is that there is currently no mandatory medical device registration or approval process which means we can get down to business right away.”

Based in North Point, Hong Kong, Pacific Medical Systems focuses on the marketing, sales and after sales support of innovative medical products in the Asia Pacific region. Members of the Pacific team are highly skillful and experienced professionals with track records from multinational companies in the medical field.

The distribution agreement between the Company and Pacific is for an initial term of three years, renewable thereafter. The minimum sales order commitment required by the agreement comprises a total of 11,800 units of the OxySure Model 615 and OxySure Replacement Cartrdges over the initial three year period.

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. www.OxySure.com
 
 
 
 
 
Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

Investor Contact:
Christian Hansen
Maximum Performance Advisors, Inc.
858-381-4677
christian@maximumperformanceadvisors.com

Additional Information

●
Company Website
●
Investor Presentation
●
Analyst Research Report
●
Recent quarterly report
●
Recent news clip: OxySure Saves Baseball Player
●
Matt Lauer on Today Show: Kylee Shea
GRAPHIC 3 img01.jpg begin 644 img01.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@("`@(! M`@("`@,"`@,#!@0#`P,#!P4%!`8(!PD("`<("`D*#0L)"@P*"`@+#PL,#0X. M#PX)"Q`1$`X1#0X.#O_;`$,!`@,#`P,#!P0$!PX)"`D.#@X.#@X.#@X.#@X. M#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#O_``!$(`#D` MR`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/W\H)P,G@#J317@.J:M=?$[Q->:98WA(^]G\O/Q>+CAHI)Z"(^CS8*C\,UQ=]\3_C#8HUW)\(\V*\F.*],T M@'_``3_X[7J6GPV.EZ5#8:;9PV-G$N(X8$"*H^@J]]JKPZE+'U]98EP?:$8V M7_@2DW]ZOV1QRA7GJZC7HE;\4V>5^#?VBO"?B/58]-UJUE\*ZA(VU#9@;3_`+P`]Z^A,Y&1R#T-?G+\=--LK3]H"\>QC6+[5:1W%PJ#CS&W!C]2 M%!/N:]\_9S\?76L>'KKP;J]P9KS3HA)82.W1K;5;6]#S\)CJCQ#P]=W>R>U_4^GJ***_3#Z0****`"BBB M@`HHK\S?VAOVI?%%Q\1]2\"_#:^?1]-L+AK6[U2UYN;R53M98V_@0'(!7YB1 MG('%?09/D^+SK$^QP]E;5M[)?ULCY'B+B/+^&L%]9Q=W=VC%:N3[+]6]%ZV1 M^F5%?C[)\`?VFKK0%\336.JS3NGG>4^N#[;Z\H9-P;_9Z^U?3G[(W_"Y+O6O M%#>/-8UJ/P[I:K:0Z;K43&5KD\DAI!O4(H&1G!WCTKZ''\-8;"8*>)HXRG4Y M-TM]7:RLW^A\CE7&F-Q^94L%B,MJT?:7Y9/:R5[NZC96[-OR/N:BBBOSX_7` MHHHH`****`"BBB@`HHHH`\S^+FN76B_!34!I[&/4=0=;&V93@J9."1[A=WXU MRNBQVFA^%['2;,!+>UA$:X[XZM]28 M2:VL5L\F=Q4<`=Z^$Q]?V693E+I%)>FK?WO?T1X]:?+B&WV5OU/3#J4:IN>0 M(OJS8%8VL>-='T/3)+B\O4>0#*6\3AI)#Z`#^9XKP'4UO]7OFGOIFDY^5,_( M@]`*R_[%7^[7SM7.<3JJ4/1M_I_P3SI8NI]E''^([V\\2^,[[6KY0)KF3(0< MB-0,*H^@`%=]\$8IK/\`:1T)HLJLBS1R8[J8V./S`_*J/]BK_=KV+X+^%V;X MES:RT?[FQMR`V/XWX'Z;J^8RW`5JF;4JC=Y._BMX!^+EUI]OXFE&BW0^T::[64!_=D\IG9R5/'TP>]>J>%OCEHDG[-W_"4 M>(KI/[9LC]ENK2,@27,^,J47T<#".YWCL.X![5^>D,?G7D,)E2%9)`IDD.$7)QD^PKULUS',N'\WJ*G M4*E)M1OY-Z6>W=&F*Q&)R_%RY9U_\OR/HWP[\4/C1\0OBC_9 M?AS5EL5N)3(8X[.)H;*+/5F9"<`>IR3]:]D^-NO^./`?PQ\+7VA^))VE6=K7 M4;J2VA)N&9-RN1LPO*MP,=>]>E?#7X>Z/\/?`D=CIY6ZOKA5DOK_`!S<-CMZ M(,\#^I-8WQTT?^V/V9/$:A=TMFBWD>!DCRV!;_QW=7TT,MS+#9%7J5Z\W7E% MR^)^[;WK+7?2S:]%IOZBP^)IX&:4GJ6A.Y0/4D%P!7".VO?%O M]H'_`*B6L7F`.JVT0_\`940?I[U\O+B#$2X>HX>E-O$5&XWO[VCWOO=II+Y] MCRWF%1Y?"G!MU).WGO\`KHCZ_P#@-KGC[Q9H6I>)/%FM27FEE_L^GP&VBC$C M#EY,JH)`X4&Z0[97CEW@D=U;`.>X M-?NMH>C6/AWPAIVAZ;%Y-C90+#"O?`'4^YZD^IKQ_P",/[/_`(*^,&GBXU*- MM'\311[+;6+11YF.RR+TD7V/([$5_3G`>9T^'*3P^.;J1J)*4FVW?7OJXZM= M[6/C^-.$L?GN6T'A*G[^@W)7?Q7M=7>S32M?3H[;E[X4_';P'\6=$A_L?44T M_P`0"/=.-:DSK MVE:7>VMU<*H7SI8XODDP.`6#IG'?.*^DSSA>CAH4L7E]3GHU9)+JUS;6?5?B MNMSCX6XYQ&.J5LOS>E[/$T(RD^BDH_%=='UTNGNK;'S/X2_:4^,_CC]I_1_" M^D^((8=)U37A##&NF0LT=L9&?V9?'6MM*(6MM%N/*; M_IHR%4'U+,HJN+L)A*><4<#A*:AHD[)*[D[:VWTL1X>YACZW#N)S3,*TJGO2 M:YI-I1A&^E]E=O[CX`^'/[4OQG\;?M">$_"[7>EK9:IJT4,PCTM=ZPE\O@YZ MA,\^U=Y^U)\?/B%\/OVA;+PSX)UQ=*M(](CGNU-I%+ND=W[NI(^4+Q[UX+^Q MSH/]L?MI:?>-'NATG3;B\)_NMM$2_K)^E<;^TMK+:[^V]X\F7+K;WJV48!S_ M`*E%C./^!*:_0EE.5SXH6'A0AR4Z7,URJSDY65UZ;'Y"^(,]I\"RQ=3%5'5J MUU&,N9W48QN[/HF]'8]6T#XP_M9?$KP>\7A%;W4+:T9A<:GIVE11M(3SL,C# M;D#^%`#CKFOHCX/>/OB=X/\`@1XB^(/Q]\036OAN`F'3;#4;!8]0FE!(.,!3 MR0552"3R<@#)^F_AIX4M_!'P&\*^%[>W6W:QTZ)+@*N-TQ4&1CZDN6)K\]/V MX?&EWJ'QKT+P/%,5TW2;`7/K3OC3\7*EC?JL<#2^J[> MY],>)K:TU#PG=Z?>?ZF5/O=U(Y!_`U\NS:+>V/QJ^(6GQB'6?`>G MZLRC_76\TELS>Y&''Y8IE_\`&/XD:K&T&B^#=/T'<,">5GNI%]P"%7\P:\K^ MPEW.?ZK$]$_X1O\`TB.-V6-G.%WG%>WZ:_A_P/\`#&XO+JZ2ST^V0S7=S)U8 M^O'))Z`#GH*^9/`^D>+K[Q&NI>(+ZXOKMSEGDXQST``PH]@`*^E+[P3H/BWP MS:Z?XFLGU"SA?S%A^TR1*6QU(1AG';.<=J]"EEWU.E*>'2=2VE]%^";M^?D; M1HNG%NFES=+['PUX_P#'?B'XO?%"UL=-M9FL?.\K2-+3J2>-[=MQ'4GA1^)- M+XE?"S5OAO\`V&U[.M]#?VV9)HU^2.=?OQ_0`J03UY]*^]O#/PQ\#>#]QQGVQ6YXE\*Z#XP\._V3XBTY-2L1*)!&SLI5AT( M92".IZ'O7P4^$<1BZ%6KBZJEB)NZ=WRJW3:^JTVTTL>#+**E6$Y5I7J/9]%_ M7X'C'[//Q`_X2;X:MX;U";=K.C(J(7/S36_1&]RN-I_X#ZU[IK6GIJ_@_5=+ MD&8[RTD@;_@2E?ZUQ_AWX5^!/"?B:/6/#^B'3M01&02K>3-E6Z@AG((^H["J M?BCXP>`?"L=]%>ZY%=:G:LR-I]J#),9%_@.!A3GN2!7V>#<\NRN-+-*D4XJU M[Z-=-TM;:>9[-'FP^%4<5)::7ONOG;4_,QE9'9'4JZG#`]C7VY^S7X#_`+-\ M*77C;48-M[J*^5I^XO9?B_(^8RC#1=3V\]EM?J^_P`C'^*G MQ(T;X5_!S4O%>L,)&B7R[&TW8:ZG(.R,?7J3V`)KYQ\$_ML?#W4O!\)\<6UY MX;UZ.,"X6UM&N+>9NYC*Y8`^C#CU/6OHCQOX7^&_Q,MY/"/C"TMM8DM'Q!+C:&91K9/*DZ*C M;ED]6^K>VVRM+U6I\L?M"_%J'XU_'/3[OP]IMS%I-E;"RTZ*2/-Q<,SDEBJY MY8D`+R>/4XKZWUCX=ZU\.?\`@CCKWA^XA:+7)K=;_5HD.3'YD\;.AQ_=C"@] MOE->H?#_`.%_P'^%^HIJFDV,LVJ1R^2NM:O;3R['W^7\DC((D.XXW+CZU]#W MC:3J-KJFD7RQ7D`M?].MIH]R&*0,,,",$$*W'M7L8[BW+9K#83+8_N:$HRU: MO)Q=TMW:^KUWWLK'SN3<&8Z4\;C\TKQEBL5"4/<^&"DK7Z7>B6FR3U=S\@/V M6/B1X9^&G[1EUJ?BV\.FZ/?:3):&[\EI!"Y='4L%!.#L(R`>HKU_]J#]I3PO MXZ^'$7@3X?WDVHZ?<7"RZKJ+6[PHZHU=U8?L]?LUZ9X4M;&ZTF M7621Y[WL]U=-,!RN93%M$2Y5AA@HR#W!KVL3Q/P77S.&:2G*52-O=7+9-;-W M:U7E*VQ\G@.&N.,/D=7(J=2A"C*_O\S2DEQO;_QTFOU MX\'>"_A5X%^%OBJS\(V\6E>&Y'E_MITO9I-K+'M?+LQ883^Z>^1UKBM'^!?P M'^'OCGP_XFTKP]=6NLQ,;C3)([F^NSPH!;RPS#`#C[P[BL*?&>54\;C<8^:] M6,5#X=$DUK[VEY=K_>>I7X"S*IE.68!5*?+AY2E5=W[W--/W?=ULKK6VI](U M^3G[:WA74M+_`&I(/$TD+G2=:TZ(6\^/E\R$;'3/8@;&^C5^GK>,O#2I&W]J M*T;1B1I$B=DB4]Y&"XCZ'[^.AK-\1:/X&^(OA<>&_$5E:Z]I]V)6C@F1@?2OA.'<^H9/F:Q%U*-K22:O9VV\[V]=NI^I<79##B?)I8&% M11FFI1;VNM-;:V:;7E>^NQ\D_`/]I_X'=:T:U6T2::UDDB MNHD&$8,BMA@N`0V.F1FO7O"?[2WPY\(;&U^T"(QI\UNK'&$\YX2.WU;PWH]S<:H<+#JU]I]U<3,3Q^Z8Q[02/^>8&1GM7N M9EF'!%3VN(H5)NI.[4;Q48R?7O9/I=GR.2PX]H^PPN+E0C1I.*E*['[.Y)WQ*V?45T%%4,X.3P/IKMDVL9_ M"GP^"=-C;(MXQ^%=S13NPL8=KH=I;8VQJN/05M(BQIM44ZBD`4444`%?.^L? MLY^&=>^(NK^(-2US46-_=OQI\O*E9>6AYM'X"6+P4WAO_1[S38+Z*>QEN"?/V[P9DD( M'S$KN7=GY@^&Z9+]6\+Z[<6FK:;IMQ;0Z??7+3"X^U2120%T"LK1JA651C(! M91T!Z9KT:BI>`P_+RI6TMIVUT_&WW"]A3M8\GA\$ZPMK#8W$=K+:KJ"S322: MQ<2K)&+@2D?9V3RP2!C`X_"NBT?PQ>Z3?>($-ZMU8W-K%;Z<)"QDA1!)\CD_ M>`,F`>N`,\C)[:BBG@,/3DI+=;?HXT*<6GV/.X?`<<8\.HVH7T<=E9M M'.C_I'C-O\,;ZS\.2 MZ/!J,#:;=))]O1PW^D,A8VYZ8'+#?UR$4#(%=M?>%Y-0U#PZTUY-;PZ?9RPR MFTNI(9&9A$!AEP2OR-D$^E=A14T\OPM*/+&.FGX.Z_'7U;[DQP]**LEV_`X& M'P[JVAPZMI_AV'3Y--OW\P/?3R^9`YC6-B1M;S0=H;EE)).3WK%NO`.L07L; M:#KBV,-I$IL/,W;A,Z+#,[XZ@QKN4?WV8GM7K%%$L!AYKE=[+:SM;KI;SU^2 M[`Z%-JW](\Y_X175H-)UKP_8QV%OH-_*H69IW,T,7DQQ%1'LP6Q&<'?W!]JR M['P/K"Z3I.G7C+!!;2QM-<6VOW;.P0'_`%:%0(R<_P`)&!QTKUJBAY?AW*[] M.FU[VVV_'S!X>FV<[X=T-M"CU:'[0]S#<7QGA>:=I9=IC1<.[